Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Nsaids as a drug repurposing strategy for biofilm control
Publication

Nsaids as a drug repurposing strategy for biofilm control

Title
Nsaids as a drug repurposing strategy for biofilm control
Type
Article in International Scientific Journal
Year
2020
Authors
Leão, C
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Anabela Borges
(Author)
FEUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Simões M
(Author)
FEUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Journal
Title: Antibiotics Imported from Authenticus Search for Journal Publications
Vol. 9 No. 591
Pages: 1-19
Publisher: MDPI
Indexing
Publicação em ISI Web of Knowledge ISI Web of Knowledge - 0 Citations
Publicação em ISI Web of Science ISI Web of Science
Other information
Authenticus ID: P-00S-QSF
Abstract (EN): Persistent infections, usually associated with biofilm-producing bacteria, are challenging for both medical and scientific communities. The potential interest in drug repurposing for biofilm control is growing due to both disinvestment in antibiotic R&D and reduced efficacy of the available panel of antibiotics. In the present study, the antibacterial and antibiofilm activities of four non-steroidal anti-inflammatory drugs (NSAIDs), piroxicam (PXC), diclofenac sodium (DCF), acetylsalicylic acid (ASA) and naproxen sodium (NPX) were evaluated against Escherichia coli and Staphylococcus aureus. The minimum inhibitory/bactericidal concentrations (MICs and MBCs) and the dose¿response curves from exposure to the selected NSAIDs were determined. MICs were found for PXC (800 µg/mL) and ASA (1750 µg/mL) against E. coli, and for DCF (2000 µg/mL) and ASA (2000 µg/mL) against S. aureus. No MBCs were found (>2000 µg/mL). The potential of NSAIDs to eradicate preformed biofilms was characterized in terms of biofilm mass, metabolic activity and cell culturability. Additionally, the NSAIDs were tested in combination with kanamycin (KAN) and tetracycline (TET). ASA, DCF and PXC promoted significant reductions in metabolic activity and culturability. However, only PXC promoted biofilm mass removal. Additive interactions were obtained for most of the combinations between NSAIDs and KAN or TET. In general, NSAIDs appear to be a promising strategy to control biofilms as they demonstrated to be more effective than conventional antibiotics. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Language: English
Type (Professor's evaluation): Scientific
Documents
We could not find any documents associated to the publication with allowed access.
Related Publications

Of the same journal

Spun Biotextiles in Tissue Engineering and Biomolecules Delivery Systems (2020)
Another Publication in an International Scientific Journal
Miranda, CS; Ribeiro, ARM; Homem, NC; Felgueiras, HP
Prevalence and Impact of Biofilms on Bloodstream and Urinary Tract Infections: A Systematic Review and Meta-Analysis (2021)
Another Publication in an International Scientific Journal
Pinto, H; Simoes, M; Anabela Borges; Simões M
New Insights on Biofilm Antimicrobial Strategies, 2nd Volume (2022)
Another Publication in an International Scientific Journal
Azevedo, AS; Melo, LDR
New Insights on Biofilm Antimicrobial Strategies (2021)
Another Publication in an International Scientific Journal
Melo, LDR; Azevedo, NF
Looking beyond Typical Treatments for Atypical Mycobacteria (2020)
Another Publication in an International Scientific Journal
Bento, CM; Gomes, MS; Silva, T

See all (61)

Recommend this page Top
Copyright 1996-2024 © Faculdade de Economia da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z  I Guest Book
Page created on: 2024-09-27 at 06:21:47 | Acceptable Use Policy | Data Protection Policy | Complaint Portal
SAMA2